

ALLERGIC SPECIALTY MEDICATIONS FORM

PATIENT INFORMATION

Last Name _____ First Name _____

Social Security No _____ Date of Birth _____

Sex M F Weight _____ Height _____ Allergies _____

Home Phone _____ Work/Mobile _____

Home Address _____

City _____ State _____ Zip _____

PATIENT INSURANCE INFORMATION

Primary Medical Insurance _____ Medical Insurance Phone _____

Subscriber Name _____

Rx Card (PBM) _____ Group No _____

Prescription Card Bin # _____ PCN # _____

TREATMENT ARRANGEMENTS

• Start Date: _____ Ship Meds Home Doctor's Office

Teaching by: Doctor's Office Other: _____

CERTIFICATE OF MEDICAL NECESSITY

Diagnosis (ICD-10): J45.40 Moderate persistent asthma uncomplicated J45.50 Severe persistent asthma uncomplicated L20.9 Atopic dermatitis

Serum total immunoglobulin E (IgE) level (IU/mL) _____ Body Weight: _____

Other: _____

PRESCRIPTION INFORMATION

DRUG	STRENGTH	DIRECTION	QUANTITY	REFILLS
<input type="checkbox"/> DUPIXENT® (dupilumab)	<input type="checkbox"/> 300mg/2ml Prefilled Syringe	<input type="checkbox"/> Inject 600mg (2 Prefilled Syringe) Subq in different sites on day 1. <input type="checkbox"/> Inject 300mg (1 Prefilled Syringe) Subq every other week starting day 15 after initial dose. <input type="checkbox"/> Others: _____		
<input type="checkbox"/> XOLAIR® (omalizumab) <input type="checkbox"/> Vial <input type="checkbox"/> Prefilled Syringe	<input type="checkbox"/> 75mg <input type="checkbox"/> 150mg <input type="checkbox"/> 225mg <input type="checkbox"/> 300mg <input type="checkbox"/> 375mg	<input type="checkbox"/> Inject _____ mg/dose Subq every 2 weeks. <input type="checkbox"/> Inject _____ mg/dose Subq every 4 weeks. <input type="checkbox"/> Others: _____		
<input type="checkbox"/> NUCALA (mepolizumab)	<input type="checkbox"/> 100mg	<input type="checkbox"/> Inject 100mg Subq once every 4 weeks. <input type="checkbox"/> Others: _____		
<input type="checkbox"/> CINQAIR® (reslizumab)	<input type="checkbox"/> _____ mg/kg	<input type="checkbox"/> Inject _____ mg/kg once every 4 weeks by intravenous infusion over 20-50 minutes. <input type="checkbox"/> Others: _____		
<input type="checkbox"/> FASENRA® (benralizumab)	<input type="checkbox"/> 30mg	<input type="checkbox"/> Inject 30mg Subq every 4 weeks for the first 3 doses, followed by once every 8 weeks thereafter. <input type="checkbox"/> Others: _____		
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		

Skilled nursing visit for self injection training and one additional visit with next dose if needed.

Physician Signature **X**: _____ DAW (Dispense as Written) Date: _____

Physician Name: _____ Phone: _____ Fax: _____ Office Contact: _____

Physician Address: _____ NPI: _____ DEA: _____

IMPORTANT NOTICE: This message may contain privileged and confidential information and is intended only for the individual only for the individual named. If you are not the named addresses, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake. Then destroy this document. Please direct all verification or notification to the above mentioned physician's office.

By Signing this prescription and using Southside pharmacy's services you authorize Southside Pharmacy to contact Insurance companies for prior authorization purposes on your behalf.